➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
McKinsey
Colorcon

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for QGC001


Email this page to a colleague

« Back to Dashboard

What is the drug development status for QGC001?

QGC001 is an investigational drug.

There have been 10 clinical trials for QGC001. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2020.

The most common disease conditions in clinical trials are Hypertension, Ventricular Dysfunction, and Myocardial Infarction. The leading clinical trial sponsors are Quantum Genomics SA, PRA Health Sciences, and Eurofins Optimed.

There are three US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for QGC001
TitleSponsorPhase
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant HypertensionPRA Health SciencesPhase 3
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant HypertensionQuantum Genomics SAPhase 3
Firibastat in Treatment-resistant HypertensionQuantum Genomics SAPhase 3

See all QGC001 clinical trials

Clinical Trial Summary for QGC001

Top disease conditions for QGC001
Top clinical trial sponsors for QGC001

See all QGC001 clinical trials

US Patents for QGC001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
QGC001   Get Started Free Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR)   Get Started Free
QGC001   Get Started Free Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Paris, FR)   Get Started Free
QGC001   Get Started Free Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Massy, FR)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for QGC001

Drugname Country Document Number Estimated Expiration Related US Patent
QGC001 Austria AT455097 2023-08-06   Get Started Free
QGC001 Canada CA2533432 2023-08-06   Get Started Free
QGC001 Cyprus CY1109950 2023-08-06   Get Started Free
QGC001 Germany DE602004025119 2023-08-06   Get Started Free
QGC001 Denmark DK1651596 2023-08-06   Get Started Free
QGC001 European Patent Office EP1651596 2023-08-06   Get Started Free
QGC001 Spain ES2339354 2023-08-06   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Harvard Business School
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.